Xhonneux R - Search Results

1

Cardiovascular effects of dl-nebivolol and its enantiomers--a comparison with those of atenolol.

Van de Water A, Xhonneux R, Reneman RS, Janssen PA. Van de Water A, et al. Among authors: xhonneux r. Eur J Pharmacol. 1988 Oct 26;156(1):95-103. doi: 10.1016/0014-2999(88)90151-3. Eur J Pharmacol. 1988. PMID: 3208842

2

Cardiac and hemodynamic effects of intravenous R80122, a new phosphodiesterase III inhibitor, in a canine model of myocardial ischemia and heart failure.

Van de Water A, Xhonneux R, Reneman RS, Janssen PA. Van de Water A, et al. Among authors: xhonneux r. J Cardiovasc Pharmacol. 1992 Jul;20(1):18-24. J Cardiovasc Pharmacol. 1992. PMID: 1383627

3

The l-enantiomer of nebivolol potentiates the blood pressure lowering effect of the d-enantiomer.

Xhonneux R, Wouters L, Reneman RS, Janssen PA. Xhonneux R, et al. Eur J Pharmacol. 1990 Jun 8;181(3):261-5. doi: 10.1016/0014-2999(90)90087-m. Eur J Pharmacol. 1990. PMID: 1974517

4

Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist.

Van de Water A, Janssens W, Van Neuten J, Xhonneux R, De Cree J, Verhaegen H, Reneman RS, Janssen PA. Van de Water A, et al. Among authors: xhonneux r. J Cardiovasc Pharmacol. 1988 May;11(5):552-63. doi: 10.1097/00005344-198805000-00007. J Cardiovasc Pharmacol. 1988. PMID: 2455841

5

Nebivolol is devoid of intrinsic sympathomimetic activity.

Janssens WJ, Van de Water A, Xhonneux R, Reneman RS, Van Nueten JM, Janssen PA. Janssens WJ, et al. Among authors: xhonneux r. Eur J Pharmacol. 1989 Jan 2;159(1):89-95. doi: 10.1016/0014-2999(89)90047-2. Eur J Pharmacol. 1989. PMID: 2565239

6

Cardiovascular and some respiratory effects of high doses of alfentanil in dogs.

D'Aubioul J, Van Gerven W, Van de Water A, Xhonneux R, Reneman RS. D'Aubioul J, et al. Among authors: xhonneux r. Eur J Pharmacol. 1984 Apr 13;100(1):79-84. doi: 10.1016/0014-2999(84)90317-0. Eur J Pharmacol. 1984. PMID: 6144553

7

Cardiac and hemodynamic effects of intravenous R 80122, a new phosphodiesterase III inhibitor, in anesthetized and awake dogs.

Van de Water A, d'Aubioul J, Van Gerven W, de Chaffoy de Courcelles D, Freyne E, Xhonneux R, Reneman RS, Janssen PA. Van de Water A, et al. Among authors: xhonneux r. Arch Int Pharmacodyn Ther. 1992 Mar-Apr;316:60-74. Arch Int Pharmacodyn Ther. 1992. PMID: 1530374

8

Interaction between S2-serotonergic and alpha 1-adrenergic receptor activities at vascular sites.

Van Nueten JM, Janssens WJ, Xhonneux R, Janssen PA. Van Nueten JM, et al. Among authors: xhonneux r. J Cardiovasc Pharmacol. 1988;11 Suppl 1:S10-5. J Cardiovasc Pharmacol. 1988. PMID: 2459506 Review.

9

An improved method to correct the QT interval of the electrocardiogram for changes in heart rate.

Van de Water A, Verheyen J, Xhonneux R, Reneman RS. Van de Water A, et al. Among authors: xhonneux r. J Pharmacol Methods. 1989 Nov;22(3):207-17. doi: 10.1016/0160-5402(89)90015-6. J Pharmacol Methods. 1989. PMID: 2586115

10

Cardiovascular effects of ketanserin in closed-chest anesthetized dogs.

van de Water A, Wouters L, Xhonneux R, Reneman S. van de Water A, et al. Among authors: xhonneux r. Arch Int Pharmacodyn Ther. 1985 Jun;275(2):267-78. Arch Int Pharmacodyn Ther. 1985. PMID: 3161481

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

51 results

Search Page

Filters